BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Sunesis Pharmaceuticals, Inc. 

395 Oyster Point Boulevard
Suite 400
South San Francisco  California  94080  U.S.A.
Phone: 650-266-3500 Fax: 650-266-3501


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical

Segment
Biotechnology

Collaborations

Merck & Co., Inc.  Alzheimer's disease, Antivirals

Biogen Idec, Inc. (California)  Cancer Therapeutics

Johnson & Johnson Pharmaceutical Research & Development, LLC (CA)  Inflammatory and Autoimmune Diseases





 Company News
Sunesis Pharmaceuticals, Inc. (SNSS) To Present At The 2014 Wedbush Life Sciences Management Access Conference 8/6/2014 8:40:01 AM
Sunesis Pharmaceuticals, Inc. (SNSS) Reports Second Quarter 2014 Financial Results And Recent Highlights 8/5/2014 7:31:01 AM
Sunesis Pharmaceuticals, Inc. (SNSS) To Host Conference Call On August 5th To Discuss Second Quarter 2014 Financial Results And Recent Highlights 7/29/2014 8:52:16 AM
Sunesis Pharmaceuticals, Inc. (SNSS) Announces European Medicines Agency Acceptance Of Pediatric Investigation Plan For Qinprezo™ (Vosaroxin) For AML 7/9/2014 10:45:28 AM
Sunesis Pharmaceuticals, Inc. (SNSS) To Present At The 2014 Wells Fargo Healthcare Conference 6/11/2014 7:29:13 AM
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Presentation Of Positive Updated Results From Ongoing MD Anderson Cancer Center-Sponsored Trial Of Vosaroxin In AML And High-Risk MDS At American Society of Clinical Oncology 2014 Annual Meeting 6/2/2014 10:06:35 AM
Sunesis Pharmaceuticals, Inc. (SNSS) To Present At Upcoming Investor Conferences 5/14/2014 10:43:39 AM
Sunesis Pharmaceuticals Reports First Quarter 2014 Financial Results And Recent Highlights 5/7/2014 8:57:12 AM
Sunesis Pharmaceuticals, Inc. (SNSS) To Host Conference Call On May 7th To Discuss First Quarter 2014 Financial Results And Recent Highlights 4/30/2014 9:11:28 AM
Sunesis Pharmaceuticals, Inc. (SNSS) Announces MD Anderson Sponsored Study Of Vosaroxin In AML And High-Risk MDS Poster To Be Presented At American Society of Clinical Oncology 2014 4/22/2014 9:13:26 AM
12345678910...